HRD1 attenuates the high uptake of [<SUP>18</SUP>F]FDG in hepatocellular carcinoma PET imaging

Ai-Mei Li,Xia-Wen Lin,Jing-Tao Shen,Min Li,Qi-Huang Zheng,Zheng-Yang Zhou,Ming Shi
DOI: https://doi.org/10.1016/j.nucmedbio.2021.02.006
IF: 2.947
2021-01-01
Nuclear Medicine and Biology
Abstract:Introduction: Due to individual deviations in tumor tissue uptake, the role of [F-18]fluorodeoxyglucose ([F-18]FDG) positron emission tomography (PET) in hepatocellular carcinoma (HCC) diagnosis is limited. beta-Hydroxy beta-methylglutaryl-CoA reductase degradation 1 (HRD1) plays a key role in clearing misfolded proteins. This study is aimed to investigate the role and mechanism of HRD1 in [F-18]FDG uptake for the diagnosis of HCC. Methods: HRD1 expression level was detected using immunohistochemical (IHC) staining in 9 HCC patients. [F-18] FDG PET/CT scans were conducted before treatment. [F-18]FDG uptakes in HRD1 overexpressed and knockdown transgenic models were measured by.-counter and microPET imaging. The GLUT1-HRD1 complex was examined by co-immunoprecipitation and IHC assays. GLUT1 expression in different cell lines, xenograft models and HCC patients was evaluated by Western blot and IHC assays. Results: HRD1 was highly expressed in the HCC tumors of patients with low[F-18]FDG uptake, while the HRD1 expression was obviously low in the higher [F-18]FDG uptake group. Both in vitro and in vivo studies found that HRD1 significantly inhibited [F-18]FDG uptake in HCC Huh7 cell lines and animal models. Furthermore, the co-location and interaction of HRD1 with GLUT1 were detected, and the results also indicate that HRD1 could induce the degradation of GLUT1 in vitro and in vivo. Conclusion: HRD1 inhibits the high uptake of [F-18]FDG in HCC tumor cells by inducing degradation of GLUT1, which leads to decreased diagnostic efficiency of [F-18]FDG PET imaging for HCC. Advances in knowledge: This study suggests that HRD1 inhibits the high uptake of [F-18]FDG in HCC tumor by inducing degradation of GLUT1. Implications for patient care: HCC diagnosis with [F-18]FDG PET should be accompanied by determination of HRD1 expression, and patients with high tumor HRD1 expression might be unsuitable for [F-18]FDG PET. (C) 2021 Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?